stockrow
Friday 6 November 2026
Export IOVA’s income statement to Excel — free account
Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
7.99
0.25
+3.23%
Follow IOVA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 4 | 6 | — |
| (55.50%) | (47.51%) | (40.36%) | (29.11%) | ||
| (42.88%) | (37.40%) | (31.76%) | (23.26%) | ||
ROIC |
(62.77%) | (55.59%) | (42.96%) | (17.72%) | |
Return on Tangible Assets |
(89.79%) | (75.53%) | (59.22%) | (38.48%) | |
Average Days of Receivables |
114.21 | 104.48 | 114.70 | 103.04 | |
Free Cash Flow per Share |
(0.94) | (0.73) | (0.66) | 0.00 | |
Free Cash Flow |
(336.24) | (305.02) | (296.39) | (216.05) | |
Capital Expenditures |
(33.84) | (34.23) | (32.21) | (26.10) | |
| Other line items | |||||
Cash ROIC |
(33.77%) | (29.47%) | (28.67%) | (26.59%) | |
Accounts Receivable Turnover |
3.47 | 3.74 | 4.01 | 4.36 | |
Accounts Payable Turnover |
6.97 | 5.25 | 5.76 | 0.00 | |
Inventory Turnover |
3.36 | 2.79 | 3.18 | 0.00 | |
Average Days of Payables |
46.70 | 79.03 | 57.05 | 0.00 | |
Days of Inventory on Hand |
108.92 | 123.19 | 121.01 | 0.00 | |
Tax Rate |
(0.01) | 0.00 | (0.01) | (0.01) | |
Research and Development Expense of Revenue |
113.95% | 100.41% | 82.38% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
57.81% | 51.63% | 45.90% | 0.00% | |
Share Based Compensation of Revenue |
23.37% | 17.48% | 14.38% | 12.31% | |
Operating CF/Net income |
0.77 | 0.77 | 0.91 | 0.86 | |
Depreciation/Fixed assets |
0.31 | 0.30 | 0.30 | 0.00 | |
Capex/Depreciation |
(0.84) | (0.86) | (0.82) | 0.00 | |
Revenue per Share |
0.74 | 0.68 | 0.72 | 0.00 | |
Operating CF per Share |
(0.85) | (0.65) | (0.59) | 0.00 | |
Capex per Share |
(0.09) | (0.08) | (0.07) | 0.00 | |
Capex to Sales |
0.13 | 0.12 | 0.10 | 0.07 |
Columns are period end dates · fundamentals updated 5 Nov 2026